Predictive factors of poor response to intravenous cyclosporine in steroid-refractory ulcerative colitis;Factores predictivos de mala respuesta precoz a la ciclosporina endovenosa en la colitis ulcerosa grave corticorrefractaria

Revista Espanola de Enfermedades Digestivas

Volumn 101, Issue 3, 2009, Pages 163-171

  Huaman Rios J W ^a   Casellas Jordá, Francesc ^a   Malagelada Benapres J R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cyclosporine; Predictive factors; Steroid refractory; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PATIENT ASSESSMENT; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; FORECASTING; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

ADRENAL CORTEX HORMONES; ADULT; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; TREATMENT FAILURE;

EID: 67650639279     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082009000300002     Document Type: Article

References (43)

1. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007; 133: 1670-1689
2. Loftus E. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517 (Pubitemid 38649869)
3. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 41: 299-315.
4. Abu-Suboh M, Casellas F, Vilaseca J, Malagelada JR. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev Esp Enferm Dig 2004; 96: 539-547 (Pubitemid 39378306)
5. Benazzato L, D'Incà R, Grigoletto F, Perissinotto E, Medici V, Angriman I, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 36: 461-466 (Pubitemid 41115449)
6. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-1070
7. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845 (Pubitemid 24188135)
8. Carbonnel F, Boruchowicz A, Duclos B, Soulé JC, Lerebours E, Lémann M, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-2476 (Pubitemid 27041805)
9. Conor G, Laurence J. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 141-169 (Pubitemid 38737265)
10. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answer and remaining questions. Gastroenterology 1995; 109: 1001-1003
11. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811 (Pubitemid 40824691)
12. Rutgeers P, Sandborn W, Reinisch W, Olson A, Johanns J, Travers S, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 (Pubitemid 41770166)
13. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123-128 (Pubitemid 46806219)
14. Aberra F, Lichtenstein G. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006; 33: 821-836
15. Rutgeerts P, Van Assche G. Review article: infliximab therapy for inflammation bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23: 451-463 (Pubitemid 43381999)
16. Willert R, Lawrance I. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14: 2544-2549 (Pubitemid 352037744)
17. Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, et al. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13: 2193-2197 (Pubitemid 46851155)
18. Susuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006; 51: 2031-2038 (Pubitemid 44832586)
19. Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 2007; 39: 422-429 (Pubitemid 46506183)
20. Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910 (Pubitemid 26231777)
21. Bernal I, Mañosa M, Domenech E, García-Planella, Navarro M, Cabré E, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006; 51: 1434-1438 (Pubitemid 44315813)
22. Carbonnel F, Gargouri D, Lémann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-278 (Pubitemid 30145314)
23. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
24. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice and Parameters committee. Am J Gastroenterol 2004; 99: 1371-1385 (Pubitemid 39062279)
25. Stange EF. European evidence-based Consensus on the diagnosis and management of ulcerative colitis. J Crohn Colitis 2008; 2: 1-62.
26. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048
27. D'Haens, Sandborn WJ, Feagan BG, K, Hanauer SB, Irvine EJ, Lémann M, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786 (Pubitemid 46306135)
28. Van AG, D'Haens G, Noman M Vermeire S, Hiele M, Asnong K, et al. Randomized double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031
29. Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006; 12: 1131-1135 (Pubitemid 44847470)
30. Silverberg MS, Sattsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Supl. A): 5A-36A.
31. Stein R, Cohen R, Hanauer S. Complications during cyclosporine therapy for inflammatory bowel disease. Gastroenterology 1997; 112: A1096.
32. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporinein ulcerative colitis: A five-year experience. Am J Gastroenterol 1999; 94: 1587-1592
33. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory of ulcerative colitis. J Clin Gastroenterol 1995; 90: 2093-2096
34. Message L, Bourrelle A, Lahaire D, Quinton A, Galmiche JP, Lamouliatte H, et al. Efficacy of intravenous cyclosporine in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005; 29: 231-235 (Pubitemid 40516308)
35. Sands B. New Therapies for the treatment of inflammatory bowel disease. Surg Clin North Am 2006; 86: 1045-1064 (Pubitemid 44189476)
36. Actis G, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long-term retrospective cohort study. BMC Gastroenterology 2007; 7: 1-6. (Pubitemid 46604973)
37. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-1087 (Pubitemid 38703520)
38. Solem CA, Loftus Jr EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-712 (Pubitemid 41271173)
39. Chang J, Cohen R. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am 2004; 33: 235-250 (Pubitemid 38737269)
40. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporine treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 95: 2000-2008 (Pubitemid 30629298)
41. Cacheux W, Seksik P, Lemmann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103: 637-642
42. Aceituno M, García-Planella E, Heredia C, Zabana Y, Feu F, Domènech E, et al. Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008; 14: 347-352
43. Ando T, Nishio Y, Watanabe O, Maeda O, Ishiguro K, Ishikawa D, et al. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol 2008; 14: 2133-2138